Our results suggest the presence
of a bimodal distribution of age at onset in BD according to the polarity of the index episode, and denote that an early onset BD, irrespective of polarity, may be a more serious subtype of the disorder. (C) 2010 Elsevier Ireland Ltd. All rights reserved.”
“Under the European Community (EC) Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), the risk to humans may be considered controlled if the estimated exposure levels to a substance do not exceed the appropriate derived no-effect level (DNEL). In order to address worker exposure, DNELs are derived for the worker population. The most significant route of exposure to workers to both soluble and sparingly soluble tungsten substances is through inhalation. In order to meet the REACH registration requirements, occupational long-term inhalation DNELs were developed according to the ICG-001 solubility dmso European Chemical Agency (ECHA) REACH guidance on characterization of dose-response for
human health. The inhalation DNELlong-term for sodium tungstate, from which all other soluble tungsten substance DNELs were derived, is 3 mg sodium tungstate/m(3) (1.7 mg W/m(3)), and the inhalation DNELlong-term for tungsten blue oxide, from which all other sparingly soluble tungsten substance DNELs were derived, is 7.3 mg tungsten blue oxide/m(3) (5.8 mg tungsten/m(3)). Although derived using different methodologies and supported by different studies, the occupational inhalation DNELs(long-term) for soluble and sparingly soluble tungsten compounds are similar to the current National selleck products Institute for SB-3CT Occupational Safety and Health (NIOSH) recommended exposure level (REL) and the American Conference of Industrial Hygienists (ACGIH) threshold limit value (TLV) 8-h time weighted average (TWA) of 1 mg tungsten/m(3) for soluble tungsten compounds and 5 mg tungsten/m(3) as metal and insoluble tungsten compounds.”
“Few studies to date have been performed to investigate impulsivity and aggressivity in patients with bipolar disorder (BD) and borderline personality disorder
(BPD); the primary aim of the present study was to evaluate the impact of co-morbidity of BPD on impulsivity and aggressivity in patients affected by BD. A total of 57 patients (male = 20, female = 37) affected by BD (BD-I 51%; BD-II 49%) in clinical stable remission were recruited; 28 patients were affected by BD (49.1%), 18 by BD and BPD (31.6%) and 11(19.3%) by BD plus other personality disorders (OPD) (19.3%). They were assessed with the Structured Clinical Interview for DSM-IV (SCID)-I and SCID-II, and were evaluated by means of the Clinical Global Impression (CGI)-severity and Global Assessment Functioning (GAF) scales, the Barratt Impulsivity Scale (BIS-11) and the Aggression Questionnaire (AQ).